Repolarization alternans: from bedside signal to risk stratification

Repolarization alternans is a beat-to-beat change in ventricular repolarization, seen as alternating T-wave morphology, amplitude, or timing on the electrocardiogram. The phenomenon may be visible on a standard tracing as macroscopic T-wave alternans, or detected as microvolt-level T-wave alternans through specialised signal-processing methods. Its clinical importance lies in what it may reveal about unstable ventricular electrical behaviour before sustained ventricular tachycardia or fibrillation occurs.

The signal is clinically useful only when interpreted alongside the patient’s substrate, symptoms, rhythm history, medications, and ventricular function. For Australian clinicians, that means connecting electrophysiology expertise in centres such as Sydney, Melbourne, Brisbane, Perth, and Adelaide with practical pathways for patients in regional and remote communities. Repolarization alternans can support risk assessment, but it should not replace established indications for implantable devices, ablation, genetic testing, or treatment of reversible disease.

What the alternating waveform represents

At the cellular level, repolarization alternans often reflects instability in calcium cycling and action-potential duration. When intracellular calcium release varies from beat to beat, the duration and shape of ventricular repolarization can change in parallel. This creates spatial and temporal heterogeneity, increasing the likelihood that a premature ventricular complex will encounter areas with different recovery states.

Macroscopic T-wave alternans may be apparent during marked QT prolongation, bradycardia, electrolyte disturbance, or severe myocardial disease. Microvolt T-wave alternans is subtler and generally requires controlled conditions, high-resolution recording, and specialised analytical software. Alternans can also involve the QT interval, ST segment, or other repolarization markers, although the clinical literature has focused most heavily on T-wave behaviour.

The finding is therefore a marker of electrical vulnerability rather than a diagnosis in itself. It may arise in ischaemic cardiomyopathy, dilated or hypertrophic cardiomyopathy, heart failure, long-QT syndromes, Brugada syndrome, and some inflammatory or infiltrative conditions. The underlying disease and the quality of the recording determine how much weight the result deserves.

Detecting the signal at the bedside

A conventional 12-lead ECG remains the first practical step. It can identify prolonged QT, T-wave morphology, conduction disease, ventricular ectopy, prior infarction, and patterns that suggest inherited arrhythmia syndromes. Alternans should be considered when T waves appear to alternate in polarity or amplitude on consecutive beats, particularly during a change in rate or after an ectopic beat.

The tracing must be reviewed for artefact. Muscle tremor, loose electrodes, baseline wander, respiratory movement, and alternating QRS amplitude can imitate repolarization alternans. A repeat ECG with careful skin preparation and stable lead placement is often more informative than a technically compromised recording. Automated QT measurements should be checked manually, especially when T waves are bifid, low amplitude, or merged with U waves.

Provocation matters. Alternans may become more apparent with increased heart rate, but exercise testing can also introduce motion artefact and catecholamine-driven changes that complicate interpretation. If exercise is used, the protocol, lead configuration, achieved rate, symptoms, ectopy, and recovery phase should be documented. In a patient taking a QT-prolonging medicine, review of prescribed drugs, over-the-counter products, and supplements is essential before attributing the finding to structural disease.

Australian practice adds logistical considerations. A patient from a regional town may have an ECG recorded in a general practice, urgent care service, or district hospital and then reviewed through a metropolitan electrophysiology network. Digital transfer and telehealth can improve access, but the original waveform and calibration details must travel with the report. Heat exposure, dehydration, vomiting, and electrolyte loss during Australian summers can also amplify repolarization instability in susceptible people.

Connecting alternans with clinical substrate

Risk assessment begins with the clinical context. Syncope during exertion, a family history of sudden cardiac death, documented non-sustained ventricular tachycardia, reduced left ventricular ejection fraction, and extensive myocardial scar all increase concern. Alternans has greater significance when it sits within this pattern than when it appears as an isolated, technically uncertain ECG observation.

Imaging and rhythm monitoring provide complementary information. Echocardiography assesses chamber size, systolic function, hypertrophy, and valvular disease, while cardiac magnetic resonance can identify late gadolinium enhancement and infiltrative or inflammatory patterns. Exercise testing may reveal ventricular ectopy or abnormal blood-pressure response. Holter monitoring can establish the burden and morphology of premature ventricular contractions, couplets, and non-sustained ventricular tachycardia.

A negative alternans test should not be treated as a guarantee of safety. Results can be affected by heart rate, autonomic tone, medications, signal quality, and the timing of testing. Conversely, a positive or indeterminate result requires confirmation and correlation rather than an automatic decision for an implantable cardioverter-defibrillator. Current guideline-based risk models remain anchored in disease-specific variables, including ventricular function, genotype and phenotype, prior cardiac arrest, scar, and documented arrhythmia.

Clinicians can use the Journal of Arrhythmia as an open-access source for evolving research on repolarization markers, ventricular arrhythmias, ablation, pacing, and device therapy. Reviews and original studies are especially helpful when a promising biomarker has not yet achieved consistent performance across different populations.

Managing reversible drivers

Before escalating risk classification, correct factors that can make repolarization unstable. Potassium, magnesium, and calcium should be measured when clinically indicated, particularly in patients with diarrhoea, vomiting, diuretic use, kidney disease, or prolonged QT. Renal and hepatic function may alter exposure to antiarrhythmic and psychotropic medicines. Drug interactions should be checked rather than inferred from a medication’s broad therapeutic class.

Heart failure treatment can reduce arrhythmic burden by improving haemodynamics and remodelling, although initiation and titration need monitoring. Ischaemia, myocarditis, thyroid disease, sleep-disordered breathing, and uncontrolled sympathetic activation may each contribute to electrical instability. Treatment should address the cause rather than attempting to suppress the alternans marker alone.

Medication review is particularly important in Australia because patients may obtain products through general practice, hospital clinics, community pharmacies, online suppliers, and complementary medicine retailers. The Therapeutic Goods Administration’s regulatory framework and the Australian Register of Therapeutic Goods provide useful reference points, but clinicians still need a complete history. Medicines associated with QT prolongation should be weighed against alternatives and monitored when their use is necessary.

Lifestyle advice should be specific and realistic. Avoiding binge alcohol intake, maintaining hydration during outdoor work or sport, and observing sick-day plans can reduce avoidable physiological stress. These measures do not eliminate inherited or structural risk, but they can reduce triggers that expose an already vulnerable repolarization reserve.

Moving from a biomarker to a risk pathway

A practical pathway starts by classifying the patient: known structural heart disease, suspected inherited syndrome, unexplained syncope, or an incidental ECG finding. The next step is to verify the alternans result, exclude artefact and reversible causes, and obtain the investigations needed for that category. The final interpretation should state what the result changes, if anything, in surveillance, treatment, referral, or shared decision-making.

For a patient with cardiomyopathy and documented ventricular tachycardia, alternans may reinforce the need for specialist management but is unlikely to be the decisive variable. For a patient with unexplained syncope and a normal initial evaluation, prolonged rhythm monitoring may provide more actionable evidence than repeating an isolated alternans test. An implantable monitor report illustrates how long-term rhythm observation can clarify intermittent events that are missed by short ambulatory recordings.

The Australian healthcare setting requires attention to access and follow-up. Medicare-supported investigations, public waiting lists, private cardiology services, and travel distances can shape the order and timing of tests. A patient living outside Perth, Darwin, or regional New South Wales may need a coordinated plan that combines local ECG acquisition with metropolitan interpretation. Clear escalation instructions are essential when follow-up depends on travel, telehealth, or shared care.

Patients should understand that a risk marker is not a prediction of a particular date or event. Explain the difference between relative risk, absolute risk, and treatment thresholds, and document preferences regarding monitoring and device therapy. This conversation is especially important when an implantable device may affect employment, driving, sport, body image, or family planning.

Research priorities and clinical implementation

The central research question is whether repolarization alternans improves outcomes when added to established risk models. A useful study should define the recording method, heart-rate conditions, exclusion criteria, medication state, and endpoint consistently. It should also test performance across cardiomyopathy, inherited arrhythmia, heart failure, and post-infarction populations rather than assuming a single mechanism.

Emerging approaches combine ECG phenotyping with imaging, genetics, autonomic measures, and continuous rhythm data. Machine learning may identify patterns that are difficult to quantify visually, but model performance depends on representative datasets and external validation. Algorithms should be assessed for calibration, false-positive burden, interpretability, and clinical benefit rather than accuracy alone.

Implementation must also respect privacy and governance. ECGs, wearable recordings, genetic results, and implantable monitor data are sensitive health information, and Australian services must operate within applicable privacy obligations, including the Privacy Act 1988 and local health-service policies. Consent, secure data transfer, retention, and access rules should be clear when information moves between hospitals, private practices, researchers, and technology suppliers.

For clinicians and investigators developing this field, the journal’s author guidance sets out submission information relevant to original studies, reviews, and clinical material. High-quality reporting can help distinguish a reproducible bedside signal from a technically attractive marker that does not improve patient decisions.

Repolarization alternans belongs in a layered assessment of electrical risk. It can expose abnormal recovery of excitability, sharpen attention to reversible triggers, and encourage appropriate monitoring in selected patients. Its value is greatest when the ECG finding is technically sound, biologically plausible, and connected to a clear management pathway.

Clinicians, researchers, and trainees can follow current evidence through the Journal of Arrhythmia, compare local practice with international data, and contribute well-characterised Australian cohorts to the wider electrophysiology community. Use the signal as a reason to investigate carefully—not as a stand-alone verdict on sudden-death risk.